Table of Contents
Ayush ministry drug approvals — Delhi HC 2024
Delhi High Court · 2024-07-12 · 2024 SCC OnLine Del 4421
Public-health approvals are disclosable; proprietary formulations are not.
Case details
| Court | Delhi High Court |
|---|---|
| Decided | 2024-07-12 |
| Citation | 2024 SCC OnLine Del 4421 |
| Bench | S, a, n, j, e, e, v, , N, a, r, u, l, a, , J |
| Petitioner | Dr. K. Ramachandran |
| Respondent | Ministry of Ayush |
| RTI Act sections | §4(1)(b), §8(1)(d) |
| Outcome | Applicant allowed |
Outcome
Ayush drug-licence approval data is public health information under §4(1)(b); commercial formulations remain §8(1)(d).
Ratio decidendi
Drug licences granted for Ayurveda, Unani, Siddha and Homoeopathy formulations concern public health and are §4(1)(b) information. The commercial formulation itself is protected under §8(1)(d) as it is trade-secret property. Labelling, indications approved, and licence conditions are disclosable.
Keywords
Ayush, drug approvals, section 4(1)(b), section 8(1)(d), public health
Similar cases in the corpus
These rulings have the closest editorial ratio to this case — computed by tf-idf cosine similarity over ratio, keywords and Act sections. Useful starting points if you are researching the same point of law.
- Hospital inspection reports — CIC (CIC 2018)
- UGC foreign-university approvals — CIC 2025 (CIC 2025)
- PSU commercial terms — §8(1)(d) — CIC (CIC 2020)
- Property-tax assessment records — CIC (CIC 2020)
Related
Editorial summary, not a certified report. The ratio here is an editorial compression. Before citing this ruling in a PIO order, FAA speaking order, or any appellate filing, verify against the full reported decision. RTI Wiki is not a legal service.
Editorial summary · last reviewed 21 April 2026.
Discussion